Barinthus Biotherapeutics

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company that develops T cell immunotherapies for chronic infectious diseases, autoimmune disorders, and cancer. Previously known as Vaccitech, the company was founded in 2016 as a spin-off from the University of Oxford by professors Sarah Gilbert and Adrian V.S. Hill. In November 2023, Vaccitech rebranded to Barinthus Biotherapeutics to reflect its strategic evolution beyond vaccines.

The company gained prominence for co-inventing the Oxford-AstraZeneca COVID-19 vaccine. Its proprietary technology platforms include Chimpanzee Adenovirus Oxford (ChAdOx), Modified Vaccinia Ankara (MVA), and the SNAP synthetic platforms. These platforms are engineered to guide the body's T cells to either eliminate virally infected or cancer cells or to promote immune tolerance in autoimmune conditions. The business model is centered on research and development, conducting clinical trials, and the eventual commercialization of its therapeutic products. Revenue is anticipated through product sales, partnerships, and licensing agreements with other pharmaceutical companies.

Barinthus is advancing a pipeline of product candidates, including VTP-300 for chronic hepatitis B (HBV) infection, VTP-200 for high-risk human papillomavirus (HPV), and VTP-1000 for celiac disease. The company has received funding from investors such as Google Ventures, Sequoia Capital, and Oxford Science Enterprises.

Keywords: T cell immunotherapy, infectious diseases, autoimmune diseases, cancer treatment, ChAdOx, MVA, SNAP platform, viral vectors, clinical-stage, biopharmaceutical, hepatitis B, HPV, celiac disease, vaccine development, immunology, University of Oxford spin-off, Sarah Gilbert, Adrian Hill, therapeutic vaccines